Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
Date and Time: November 10, 2026 at 10 a.m. ET
Format: Fireside Chat
Location: Boston, MA
Stifel 2026 Healthcare Conference
Date and Time: November 11, 2026 at 10:40 a.m. ET
Format: Fireside Chat
Location: New York, NY
UBS Global Biopharma Conference
Date and Time: November 17, 2026 at 3:20 p.m. GMT/10:20 a.m. ET
Format: Fireside Chat
Location: London, England
Jefferies Global Healthcare Conference
Date and Time: November 18, 2026 at 4 p.m. GMT/11 a.m. ET
Format: Fireside Chat
Location: London, England
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
Media gallery
